COLL COLLEGIUM PHARMACEUTICAL, INC — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$33.38

Period return

-14.53 (-30.33%)

Volume

333.4K

2026-06-05O $33.02 H $34.25 L $33.01 C $33.38MA5 $31.88MA20 $33.83MA60 $34.06MA120 $39.83

6M · 124 barsYahoo Finance · USD2025-12-08 → 2026-06-05

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 03. 20.LowBUY3 months ago
HC Wainwright & Co.: Buy
US analyst rating / recommendation change.
2026. 03. 19.LowBUY3 months ago
Needham: Buy
US analyst rating / recommendation change.
2026. 02. 27.LowBUY3 months ago
Needham: Buy
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $54.33 · 6 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
HQ: Stoughton, MA, United States
Fiscal year end

2026. 01. 09.LowBUY5 months ago

Barclays: Overweight